The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models

Activation of the epidermal growth factor receptor (EGFR) signaling pathway promotes the development of hepatocellular adenoma (HCA) and carcinoma (HCC). The selective EGFR inhibitor Gefitinib was found to prevent hepatocarcinogenesis in rat cirrhotic livers. Thus, Gefitinib might reduce progression...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribback, Silvia, Sailer, Verena, Böhning, Enrico, Günther, Julia, Merz, Jaqueline, Steinmüller, Frauke, Utpatel, Kirsten, Cigliano, Antonio, Peters, Kristin, Pilo, Maria G., Evert, Matthias, Calvisi, Diego F., Dombrowski, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085651/
https://www.ncbi.nlm.nih.gov/pubmed/27669229
http://dx.doi.org/10.3390/ijms17101618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085651/
https://www.ncbi.nlm.nih.gov/pubmed/27669229
http://dx.doi.org/10.3390/ijms17101618

Ejemplares similares